Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

A recalled sickle cell drug is drawing new scrutiny from attorneys who say it may have done more harm than good, possibly ...

According to Coherent Market Insights (CMI), the global sickle cell disease treatment market size is expected to expand from USD 3.20 Bn in 2025 to USD 8.81 Bn by 2032, recording a CAGR of 15.6% ...

The model was initially launched by the Biden administration in February 2023, and CMS announced that SCD would be the first focus of the model the following January. This is the ...

Kenya is among the countries set to benefit from enhanced screening and care for sickle cell anaemia. This follows the ...

So far in 2025, the Trump administration has cut more than $1 billion in NIH grants. That includes a study on sickle cell ...

Gabriella Ngang, of Farmington Hills, is one of three in Michigan to take part in a clinical trial of a new sickle cell ...

The U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

Hemoglobinopathies Market The hemoglobinopathies market is advancing rapidly, driven by gene therapy, new drugs, and rising access for trea ...

Oxbryta is a prescription drug used to treat sickle cell disease. Learn about the common, mild, and serious side effects it can cause and how to manage them.

Oxbryta’s conditional approval in 2019 by the U.S. Food and Drug Administration gave hope to many, as few treatments exist for patients with sickle cell disease. The therapy was approved in the ...

Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.